Precigen, Inc. (PGEN) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, ladies and gentlemen, and welcome to the Precision Third Quarter 2025 Financial Results and Business Updates Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, November 13, 2025. I would now like to turn the conference over to Steve Harasim. Please go ahead. Thank you, Operator, and thank you to all those joining us for our third quarter 2025 update call. Joining me today are Helen Sabzabari, our President and CEO, Phil Tennant, our Chief Commercial Officer, Ritul Shah, our Chief Operating Officer, and Harry Tomasi, our CFO. Before we begin our prepared remarks, I remind everyone that we will be making certain forward-looking statements. These statements are based on our current expectations and beliefs. We encourage you to review the slide in this presentation and in our SEC filings, which include risks and uncertainties that could cause actual results to differ materially from today's forward-looking statements. With that, I will now turn the call over to Helen. Helen? Thank you, Steve, and thank you to all those joining us for our third quarterly update call. The approval of Paximius in August marked a monumental turning point for all those impacted by recurrent respiratory papillomatosis, or RRP. Patients, families, physicians, and the RRP Foundation alike. We would like to welcome you to the new era of RRP treatment with Pepsimus poised to become the standard of care. Pepsimus is the first and only available treatment for adults with RRP, and it represents the best data, and that's by a wide margin, ever generate...